Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.

Details

Ressource 1Download: 27125947_BIB_7F3EDF35B143.pdf (309.56 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_7F3EDF35B143
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
Journal
European heart journal
Author(s)
Laaksonen R., Ekroos K., Sysi-Aho M., Hilvo M., Vihervaara T., Kauhanen D., Suoniemi M., Hurme R., März W., Scharnagl H., Stojakovic T., Vlachopoulou E., Lokki M.L., Nieminen M.S., Klingenberg R., Matter C.M., Hornemann T., Jüni P., Rodondi N., Räber L., Windecker S., Gencer B., Pedersen E.R., Tell G.S., Nygård O., Mach F., Sinisalo J., Lüscher T.F.
ISSN
1522-9645 (Electronic)
ISSN-L
0195-668X
Publication state
Published
Issued date
01/07/2016
Peer-reviewed
Oui
Volume
37
Number
25
Pages
1967-1976
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
The aim was to study the prognostic value of plasma ceramides (Cer) as cardiovascular death (CV death) markers in three independent coronary artery disease (CAD) cohorts.
Corogene study is a prospective Finnish cohort including stable CAD patients (n = 160). Multiple lipid biomarkers and C-reactive protein were measured in addition to plasma Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0), and Cer(d18:1/24:1). Subsequently, the association between high-risk ceramides and CV mortality was investigated in the prospective Special Program University Medicine-Inflammation in Acute Coronary Syndromes (SPUM-ACS) cohort (n = 1637), conducted in four Swiss university hospitals. Finally, the results were validated in Bergen Coronary Angiography Cohort (BECAC), a prospective Norwegian cohort study of stable CAD patients. Ceramides, especially when used in ratios, were significantly associated with CV death in all studies, independent of other lipid markers and C-reactive protein. Adjusted odds ratios per standard deviation for the Cer(d18:1/16:0)/Cer(d18:1/24:0) ratio were 4.49 (95% CI, 2.24-8.98), 1.64 (1.29-2.08), and 1.77 (1.41-2.23) in the Corogene, SPUM-ACS, and BECAC studies, respectively. The Cer(d18:1/16:0)/Cer(d18:1/24:0) ratio improved the predictive value of the GRACE score (net reclassification improvement, NRI = 0.17 and ΔAUC = 0.09) in ACS and the predictive value of the Marschner score in stable CAD (NRI = 0.15 and ΔAUC = 0.02).
Distinct plasma ceramide ratios are significant predictors of CV death both in patients with stable CAD and ACS, over and above currently used lipid markers. This may improve the identification of high-risk patients in need of more aggressive therapeutic interventions.

Keywords
Acute Coronary Syndrome, Biomarkers, Ceramides, Cholesterol, LDL, Coronary Artery Disease, Humans, Prognosis, Prospective Studies, Risk Factors, Acute coronary syndrome, Biomarker, Ceramide, Coronary artery disease, LDL-cholesterol, Risk prediction
Pubmed
Web of science
Open Access
Yes
Create date
17/05/2016 18:06
Last modification date
22/08/2019 8:27
Usage data